As UK biotech gains steam, Syncona launches new Treg player while Cambridge spinout expands Series A
Since merging with the public investment firm BACIT two-plus years ago, Syncona has made steady headway in the cell and gene therapy space: It watched Autolus bag an $150M IPO, jumped into a $116 million round for Freeline and celebrated the $800 million sale of Nightstar, all the while grooming its portfolio of startups in which it typically holds a majority stake.
Now the London-based VC firm — once an independent subsidiary of the Wellcome Trust — is unveiling its next big act, squarely focused on engineering regulatory T cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.